Bissinger T, et al. Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production. Vaccine. 2019 Apr 29.
Control and prevention of rapid influenza spread among humans depend on the availability of efficient and safe seasonal and pandemic vaccines, made primarily from inactivated influenza virus particles. Current influenza virus production processes rely heavily on embryonated chicken eggs or on cell culture as substrate for virus propagation. Today´s efforts towards process intensification in animal cell culture could innovate viral vaccine manufacturing using high-yield suspension cells in high cell density perfusion processes. In this work, we present a MDCK cell line adapted to grow as single cell suspension with a doubling time of less than 20?h, achieving cell concentrations over 1?×?107?cells/mL in batch mode. Influenza A virus titer obtained in batch infections were 3.6 log10(HAU/100?μL) for total- and 109?virions/mL for infectious virus particles (TCID50), respectively. In semi-perfusion mode concentrations up to 6?×?107?cells/mL, accumulated virus titer of 4.5 log10(HAU/100?μL) and infectious titer of almost 1010?virions/mL (TCID50) were possible. This exceeds results reported previously for cell culture-based influenza virus propagation by far and suggests perfusion cultures as the preferred method in viral vaccine manufacturing.
See Also:
Latest articles in those days:
- Global pattern and determinant for interaction of seasonal influenza viruses 9 hours ago
- Spatio-temporal dynamics and drivers of highly pathogenic avian influenza H5N1 in Chile 2 days ago
- [preprint] Avian Influenza Virus Infections in Felines: A Systematic Review of Two Decades of Literature 2 days ago
- Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe 2 days ago
- Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older 2 days ago
[Go Top] [Close Window]